Close Menu

NEW YORK – Cancer Genetics reported after the close of the market on Wednesday that its first quarter revenues fell 22 percent year over year, mainly due to a non-recurring IP licensing agreement a year ago.

For the three months ended March 31, Rutherford, New Jersey-based Cancer Genetics posted total revenues of $1.4 million versus $1.8 million in the same quarter the year before. In Q1 2019, the firm had $300,000 in revenue from an IP license agreement that was unrelated to its ongoing discovery services business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.